MedPath

Mitoxantrone

Generic Name
Mitoxantrone
Drug Type
Small Molecule
Chemical Formula
C22H28N4O6
CAS Number
65271-80-9
Unique Ingredient Identifier
BZ114NVM5P
Background

An anthracenedione-derived antineoplastic agent.

Indication

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
Associated Therapies
Autologous hematopoietic stem cell transplant
Clinical Trials
Related News

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
First Posted Date
2004-04-14
Last Posted Date
2020-04-01
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
224
Registration Number
NCT00003032
Locations
🇨🇦

Humber River Regional Hospital, Weston, Ontario, Canada

🇨🇦

Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec, Quebec City, Quebec, Canada

🇨🇦

William Osler Health Centre, Brampton, Ontario, Canada

and more 22 locations

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Phase 3
Conditions
Leukemia
First Posted Date
2004-04-13
Last Posted Date
2013-11-06
Lead Sponsor
Facet Biotech
Registration Number
NCT00006045
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇳🇱

Academisch Medisch Centrum, Amsterdam, Netherlands

and more 56 locations

Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer

Phase 3
Completed
Conditions
Pain
Prostate Cancer
Quality of Life
First Posted Date
2004-04-09
Last Posted Date
2020-04-03
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
227
Registration Number
NCT00003232
Locations
🇨🇦

Cancer Care Ontario - Windsor Regional Cancer Centre, Windsor, Ontario, Canada

🇨🇦

Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada

🇨🇦

Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada

and more 18 locations

A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years

First Posted Date
2004-03-09
Last Posted Date
2017-03-30
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Target Recruit Count
175
Registration Number
NCT00079105
Locations
🇬🇧

Royal United Hospital, Bath, England, United Kingdom

🇬🇧

Kent and Canterbury Hospital, Canterbury, England, United Kingdom

🇬🇧

Saint Richards Hospital, Chichester, England, United Kingdom

and more 51 locations

Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2004-02-16
Last Posted Date
2012-07-16
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
106
Registration Number
NCT00006122
Locations
🇫🇷

Hotel Dieu de Paris, Paris, France

🇧🇪

A.Z. St. Jan, Brugge, Belgium

🇦🇹

Innsbruck Universitaetsklinik, Innsbruck, Austria

and more 15 locations

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Phase 2
Conditions
Leukemia
First Posted Date
2004-02-16
Last Posted Date
2013-09-17
Lead Sponsor
Johann Wolfgang Goethe University Hospital
Registration Number
NCT00002531
Locations
🇩🇪

Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany

Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Phase 2
Withdrawn
Conditions
Lymphoma
First Posted Date
2003-10-08
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Registration Number
NCT00005998

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2003-10-07
Last Posted Date
2014-02-20
Lead Sponsor
Children's Oncology Group
Target Recruit Count
350
Registration Number
NCT00070174
Locations
🇺🇸

Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States

🇺🇸

St. Barnabas Medical Center, Livingston, New Jersey, United States

🇺🇸

All Children's Hospital, St. Petersburg, Florida, United States

and more 145 locations

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2003-04-30
Last Posted Date
2013-12-04
Lead Sponsor
Medical Research Council
Target Recruit Count
2000
Registration Number
NCT00003436
Locations
🇬🇧

Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2003-04-30
Last Posted Date
2018-11-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
42
Registration Number
NCT00059631
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy